November 18, 2026
Health news, explained with evidence
LIVE

FDA Approves Neladalkib for Previously Treated ALK-Positive Lung Cancer

❤️ Conditions & Care 2 min read 👁 3

The FDA has granted accelerated approval to neladalkib for advanced ALK-positive non-small cell lung cancer patients who have undergone prior treatments.

FDA Approves Neladalkib for Previously Treated ALK-Positive Lung Cancer❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • FDA granted accelerated approval to neladalkib for advanced ALK-positive NSCLC.
  • Approval is based on the single-arm ALKOVE-1 trial involving 222 participants.
  • Common side effects include elevated liver enzymes, fatigue, and musculoskeletal pain.

New Targeted Option for Advanced NSCLC

Federal regulators have granted accelerated approval to the third-generation ALK inhibitor neladalkib, marketed as Nelkarmi, providing a new option for patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The indication covers individuals with unresectable locally advanced or metastatic disease who have previously received alectinib or at least two prior ALK tyrosine kinase inhibitors alongside platinum-based chemotherapy.

Approval was supported by findings from the phase I/II single-arm ALKOVE-1 clinical trial involving 222 participants. Among 67 patients previously treated solely with alectinib in the metastatic setting, the therapy prompted responses in 49%, with 76% maintaining that response for at least six months. For a broader group of 155 heavily pretreated patients who received two or more prior ALK inhibitors and chemotherapy, the response rate reached 32%. Investigators noted common adverse events included elevated liver enzymes, musculoskeletal pain, and fatigue, accompanied by prescribing warnings for hepatotoxicity, renal toxicity, and other risks.

What to know: While clinical trial data suggest promising response durations and efficacy even in some patients with brain metastases, the findings stem from a single-arm study rather than a randomized trial. Patients should consult their oncologists regarding personalized treatment sequences and potential side effects.

Source medpagetoday.com — medpagetoday.com/hematologyoncology/lungcancer/123937 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.